1851727129
Dr. Paika Podcast

Advertise on podcast: Dr. Paika Podcast

Rating
★★★★★
5
from
2 reviews
This podcast has
127 episodes
Language
English
Explicit
No
Date created
2025/11/08
Latest episode
2026/11/17
Average duration
17 min.
Release period
3 days

Description

Welcome to the Dr. Paika Podcast — where medicine, fitness, and humanity come together. Hosted by Dr. Mohammed K. Paika, M.D., double board-certified in obesity & internal medicine with over two decades of hospital experience, this show dives deep into the science of health, obesity, longevity, and mindset — but with compassion, not complexity. From hospital medicine to the gym floor, from patient care to personal growth — every episode blends real clinical insight with practical, inspiring stories that help you live better and think deeper. 💡 Topics include: Obesity & metabolic health Longevity & fitness Nutrition & preventive medicine Doctor insights from 20+ years in hospitals across the US! Mindset, mental health, and motivation 🎧 Subscribe for weekly conversations that are honest, empowering, and rooted in science — all from a doctor who believes medicine should heal the mind and body.

Unlock Dr. Paika Podcast podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from Dr. Paika Podcast podcast


Zepbound 10mg to 12.5mg? Watch This Before You Move Up (Doctor Explains)
2026/11/17
#Zepbound #Tirzepatide #GLP1 #WeightLossJourney #ObesityMedicine Thinking about moving from Zepbound 10 mg to 12.5 mg? In this video, I fact-check 4 common claims about the 10 to 12.5 step, using the FDA label and the trial data: 12.5 mg is a maintenance doseIf you’ve stalled on 10, going up will restart your weight lossHigher doses mean worse side effectsYou have to get to 15 mg eventually You’ll learn when it makes sense to stay on 10 and when you might be ready for 12.5. I also cover what the new SURMOUNT-MAINTAIN trial showed, what to do in your first 2 weeks after moving up, and 3 safety notes most people miss. I’m Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine. 📘 FREE GLP-1 Diet Cookbook (join my newsletter): https://www.drmohammedpaika.com/newsletter🎓 GLP-1 Masterclass, now with 4 student tools: https://www.drmohammedpaika.com🌐 My new website: https://www.paikahealth.com▶️ Watch next, “When Should You Increase or Decrease Your GLP-1 Dose?”: [LINK] This video is for education only and is not medical advice. Talk with your prescriber before changing your dose. ⏱️ TIMESTAMPS0:00 Moving from 10 mg to 12.5 mg2:20 Claim 1: 12.5 mg is a maintenance dose3:44 Claim 2: Stalled on 10? Going up will restart weight loss4:44 How much more does 15 mg actually add?6:52 Claim 3: Higher doses mean worse side effects8:55 Claim 4: You have to get to 15 mg eventually9:37 New data: SURMOUNT-MAINTAIN11:00 When to stay on 10 mg11:59 When you might be ready for 12.5 mg12:49 Your first 2 weeks after moving up13:50 3 quick safety notes14:52 Scorecard: all 4 claims15:44 My take16:10 GLP-1 Masterclass 📚 REFERENCES ZEPBOUND (tirzepatide) US Prescribing Information. Eli Lilly and Company; revised 8/2026.https://uspl.lilly.com/zepbound/zepbound.htmlJastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. Funded by Eli Lilly.https://pubmed.ncbi.nlm.nih.gov/35658024/Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025;15(3):e12734. Post hoc analysis; funded by Eli Lilly.https://pubmed.ncbi.nlm.nih.gov/39800653/Horn DB, Aronne LJ, et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN). Lancet. 2026;407(10545):2305-2318. Funded by Eli Lilly.https://pubmed.ncbi.nlm.nih.gov/42119587/Gorgojo-Martínez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145.https://pubmed.ncbi.nlm.nih.gov/36614945/Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from ACLM, ASN, OMA and TOS. Am J Clin Nutr. 2025;122(1):344-367.https://pubmed.ncbi.nlm.nih.gov/40450457/ Viewer comments shown in this video are public YouTube comments, quoted with names removed. They are personal experiences, not evidence.
Zepbound 2.5 mg to 5 mg? Watch This Before You Move Up (Doctor Explains)
2026/11/14
#Zepbound #Tirzepatide #GLP1 #WeightLoss #ObesityMedicine Just finished your first 4 weeks on Zepbound 2.5 mg, and now your next box says 5? Maybe the scale barely moved. Maybe you feel great on 2.5 and you’re nervous that doubling the dose will ruin it. Or maybe you’re worried about weeks of nausea and constipation. In this video, I’m Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine. I break down what 2.5 mg is really for and test 4 popular claims about this first step against the Zepbound label and the SURMOUNT trials. You’ll also get my framework for knowing whether you’re ready for 5 mg, plus a simple plan for your first 2 weeks on the new dose. You’ll learn: Why your first month on 2.5 mg doesn’t predict your long-term resultsWhether you need to feel sick for Zepbound to workWhy 2.5 → 5 mg is the biggest jump on the dose ladder, and the side effect rates on 5 mgWhy 5 mg is a full maintenance dose and not just a stepping stoneWhen it makes sense to wait before moving up, and when you’re readySafety notes on birth control pills, insulin and sulfonylureas, missed doses, and dehydration 📘 FREE GLP-1 Diet Cookbook (my go-to meals for smaller appetites, protein first): https://www.drmohammedpaika.com/newsletter🎓 GLP-1 Masterclass (what to really expect, handling side effects, your protein and calorie targets, a 36-week workout program, and a game plan for the long haul): https://drmohammedpaika.com ▶️ Next step: Zepbound 5mg to 7.5mg? Watch This Before You Move Up: https://youtu.be/PFHvEFXb4IY▶️ Zepbound 7.5mg to 10mg? Watch This Before You Move Up: https://youtu.be/C-e3LPRtDvY▶️ How Long Tirzepatide Stays in Your Body (Half-Life Explained): https://youtu.be/afUfqXaUIug This video is for educational purposes only and is not medical advice. Talk to your prescriber before changing your dose. TIMESTAMPS0:00 Moving from 2.5 mg to 5 mg1:14 Your stories from the comments2:05 Claim 1: “If the scale barely moved, it won’t work”3:29 Claim 2: “If you don’t feel sick, it’s not working”4:47 What to eat before the jump (free cookbook)5:07 Claim 3: “2.5 to 5 is a small step”6:45 Claim 4: “5 mg is just a stepping stone”8:01 How to know if you should wait on 2.5 mg9:09 Signs you’re ready for 5 mg9:32 What if 2.5 mg is working great?10:09 Your plan for the first 2 weeks on 5 mg11:06 Safety notes: the pill, low blood sugar, missed doses12:12 Recap: 4 claims, 4 verdicts13:10 What the pen can’t do for you13:48 What’s next: 5 mg to 7.5 mg REFERENCES ZEPBOUND (tirzepatide) US Prescribing Information. Eli Lilly and Company; revised 8/2026. https://uspl.lilly.com/zepbound/zepbound.htmlJastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/Rubino DM, et al. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials. Diabetes Obes Metab. 2025;27(4):1826-1835. https://pubmed.ncbi.nlm.nih.gov/39789843/Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958-971. https://pubmed.ncbi.nlm.nih.gov/39536238/Gorgojo-Martinez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145. https://pubmed.ncbi.nlm.nih.gov/36614945/Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from ACLM, ASN, OMA and TOS. Am J Clin Nutr. 2025;122(1):344-367. https://pubmed.ncbi.nlm.nih.gov/40450457/
Why Ozempic and Zepbound Wake You Up at 3 AM (Doctor Explains)
2026/11/12
#GLP1 #Ozempic #Zepbound #Insomnia #SleepApnea Waking up at 3 AM on Ozempic, Wegovy, Mounjaro or Zepbound? You’re not imagining it, and the medicine usually isn’t the whole story. In the trial that got Zepbound approved for sleep apnea, people on the drug actually reported better sleep than people on placebo. So when your sleep gets worse, something the drug changes in your body is often what’s waking you up. In this video, I’m Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine. I go through 6 possible causes of 3 AM wake-ups on a GLP-1, what the research actually shows for each one, and what you can change starting tonight: 📘 FREE GLP-1 Diet Cookbook: join my newsletter at https://www.drmohammedpaika.com🎓 GLP-1 Masterclass (side effects, protein and calorie targets, and a 12-week home exercise program): https://www.drmohammedpaika.com TIMESTAMPS0:00 Waking up at 3 AM on a GLP-11:06 Who this video is for1:36 My story: what bad sleep did to me2:52 The patient who blamed their GLP-13:30 Your best clue: the first minute after you wake4:01 Cause 1: Low blood sugar at night5:35 Cause 2: Night reflux8:16 Cause 3: A faster heart rate9:09 Cause 4: Alcohol10:10 Cause 5: Sleep apnea you don’t know you have11:50 Cause 6: Hunger, water timing & the drug itself13:24 The 30-second scorecard13:41 Your 1-week plan14:30 When to call your prescriber15:14 What you need besides this15:45 Up next REFERENCES Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391:1193-1205. https://pubmed.ncbi.nlm.nih.gov/38912654/Kanu C, et al. Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants. Sleep Med. 2025;134:106719. https://pubmed.ncbi.nlm.nih.gov/40774158/Malhotra A, et al. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: time course and association with body weight. Sleep Med. 2025;136:106853. https://pubmed.ncbi.nlm.nih.gov/41135142/FDA approves Zepbound for obstructive sleep apnea in adults with obesity (Dec 20, 2024). https://www.pharmacist.com/Blogs/CEO-Blog/fda-approves-zepbound-for-obstructive-sleep-apneaKamalinia S, et al. Risk of any hypoglycaemia with newer antihyperglycaemic agents in type 2 diabetes. Endocrinol Diabetes Metab. 2019;3:e00100. https://pubmed.ncbi.nlm.nih.gov/31922027/Katranski J, et al. Psychiatric adverse events linked to GLP-1 analogues. Int J Clin Pharm. 2025;47:1739-1747. https://pubmed.ncbi.nlm.nih.gov/40522403/Nong K, et al. Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. 2025;390:e083039. https://pubmed.ncbi.nlm.nih.gov/40813122/Mayo Clinic. Diabetic hypoglycemia: symptoms and causes. https://www.mayoclinic.org/diseases-conditions/diabetic-hypoglycemia/symptoms-causes/syc-20371525Noh Y, et al. GLP-1 receptor agonists and risk for gastroesophageal reflux disease in type 2 diabetes. Ann Intern Med. 2025;178:1268-1278. https://pubmed.ncbi.nlm.nih.gov/40658955/Liu BD, et al. Shorter-acting GLP-1 receptor agonists and gastro-oesophageal reflux disease. Gut. 2024;73:246-254. https://pubmed.ncbi.nlm.nih.gov/37739778/Hiramoto B, et al. Quantified metrics of gastric emptying delay by GLP-1 agonists: a meta-analysis. Am J Gastroenterol. 2024;119:1126-1140. https://pubmed.ncbi.nlm.nih.gov/38634551/Hoshino S, et al. Nocturnal gastroesophageal reflux and sleep depth in healthy adults. J Nippon Med Sch. 2024;91:371-376. https://pubmed.ncbi.nlm.nih.gov/39231640/Fujiwara Y, et al. Association between dinner-to-bed time and gastro-esophageal reflux disease. Am J Gastroenterol. 2005;100:2633-2636. https://pubmed.ncbi.nlm.nih.gov/16393212/Villamil Morales IM, et al. Impact of head of bed elevation in patients with GERD (IBELGA). Gastroenterol Hepatol. 2020;43:310-321. https://pubmed.ncbi.nlm.nih.gov/32229033/Zhang Y, et al. Effect of GLP-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity. Eur J Med Res. 2026;31:318. https://pubmed.ncbi.nlm.nih.gov/41582189/Ebrahim IO, et al. Alcohol and sleep I: effects on normal sleep. Alcohol Clin Exp Res. 2013;37:539-549. https://pubmed.ncbi.nlm.nih.gov/23347102/Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder. JAMA  ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
How to Prep the Day Before Your GLP-1 Shot to Avoid Side Effects
2026/11/10
#GLP1 #GLP1SideEffects #Semaglutide #Wegovy #WeightLoss One week your GLP-1 shot feels easy. The next you’re dealing with nausea, bloating, or feeling too full to eat, and you can’t figure out what changed. As a hospitalist, I’ve admitted patients whose shot week went wrong: a dose increase, days of vomiting, not enough fluids, and kidney failure. Most of those links can be planned for the day before your shot. In this video I’m Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine. I walk you through a 7-step, 24-hour prep plan: what to eat, how to hydrate, what to avoid, and the red flags that mean you should call your doctor. I also tell you how strong the evidence is for each step. If you have diabetes and take insulin or a sulfonylurea, don’t skip the warning at 16:17. 🍽️ FREE GLP-1 Diet Cookbook: drmohammedpaika.com/newsletter🎓 GLP-1 Masterclass (side effects, protein, hydration, a 12-week home exercise program): drmohammedpaika.com This video is for education only and is not medical advice. Talk to your prescriber before changing your dose or routine. TIMESTAMPS0:00 When your shot week goes wrong1:33 A hospital case: dehydration and kidney failure2:38 Why I plan the day before3:26 Side effect numbers that surprised me4:03 What’s happening inside your body5:19 What the evidence can and can’t tell us5:34 Step 1: Check your dose calendar6:53 Step 2: Shrink the last big meal9:07 Step 3: Don’t go empty either10:15 Step 4: Hydrate on purpose12:21 Step 5: Alcohol and carbonation13:33 Step 6: Sleep and planning the day after14:57 Step 7: Your rescue kit15:58 Red flags: when to call your doctor16:17 Warning if you have diabetes16:49 The 24-hour plan in 30 seconds17:02 Protecting your muscle17:39 Next steps REFERENCES Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg (STEP 1–3). Diabetes Obes Metab. 2022;24(1):94-105. https://pubmed.ncbi.nlm.nih.gov/34514682/Enebo LB, et al. Cagrilintide with semaglutide 2.4 mg, phase 1b trial. Lancet. 2021;397(10286):1736-1748. https://pubmed.ncbi.nlm.nih.gov/33894838/Hjerpsted JB, et al. Semaglutide delays first-hour gastric emptying in subjects with obesity. Diabetes Obes Metab. 2018;20(3):610-619. https://pubmed.ncbi.nlm.nih.gov/28941314/Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory. Am J Clin Nutr. 2025;122(1):344-367. https://pubmed.ncbi.nlm.nih.gov/40450457/Gorgojo-Martínez JJ, et al. Clinical recommendations to manage GI adverse events with GLP-1 receptor agonists: expert consensus. J Clin Med. 2023;12(1):145. https://pubmed.ncbi.nlm.nih.gov/36614945/Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder. JAMA Psychiatry. 2025. https://pubmed.ncbi.nlm.nih.gov/39937469/Wegovy (semaglutide) injection Prescribing Information, Novo Nordisk, revised 05/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s031,218316s00lbl.pdf ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
Zepbound 7.5mg to 10mg? Watch This Before You Move Up (Doctor Explains)
2026/11/07
#Zepbound #Tirzepatide #GLP1 #WeightLoss #ObesityMedicine Should you move up to 10 mg of Zepbound, or stay on 7.5 mg? If your weight has stalled, your hunger is creeping back, or your next box says 10 and you're not sure you need it, this video walks you through what the research actually shows. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. I break down 4 popular claims about the 10 mg dose and give each one a verdict:1. "The drug wears off, so everyone ends up needing 10 mg"2. "10 mg is where the real results are"3. "Side effects get much worse at 10 mg"4. "Once you go up, you can't come back down" You'll see what the trials show for 5, 10 and 15 mg, how side effects compare between 5 mg and 10 mg, what the new SURMOUNT-MAINTAIN trial found about stepping down, my framework for when to stay on 7.5 mg and when to move up, and what to do before your first 10 mg shot. 🍳 FREE GLP-1 Diet Cookbook (join my newsletter): https://drmohammedpaika.com/newsletter 🎓 GLP-1 Masterclass, recently updated with a 36-week workout program that starts at home and moves to the gym: https://drmohammedpaika.com ▶️ Watch next: my video on the step from 5 mg to 7.5 mg This video is for educational purposes only and is not medical advice. Talk to your prescriber before changing your dose. TIMESTAMPS0:00 Should you move up to 10 mg?1:42 A hospital case: stuck on 7.5 mg3:16 Claim 1: "The drug wears off"5:43 Claim 2: "10 mg is where the real results are"7:36 What to eat when your appetite drops8:02 Claim 3: "Side effects get much worse at 10 mg"9:46 Claim 4: "You can't come back down"12:19 Stay on 7.5 mg or move up?13:27 Before your first 10 mg shot14:26 The pill and red-flag symptoms14:48 Recap: the 4 verdicts15:47 What the pen can't do for you REFERENCES1. ZEPBOUND (tirzepatide) US Prescribing Information. Eli Lilly and Company; revised 8/2026. https://uspl.lilly.com/zepbound/zepbound.html2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/3. Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958-971. https://pubmed.ncbi.nlm.nih.gov/39536238/4. Polidori D, et al. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity. 2016;24(11):2289-2295. https://pubmed.ncbi.nlm.nih.gov/27804272/5. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/6. Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN). Lancet. 2026;407(10545):2305-2318. https://pubmed.ncbi.nlm.nih.gov/42119587/7. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from ACLM, ASN, OMA and TOS. Am J Clin Nutr. 2025;122(1):344-367. https://pubmed.ncbi.nlm.nih.gov/40450457/8. Gorgojo-Martínez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145. https://pubmed.ncbi.nlm.nih.gov/36614945/ ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
Zepbound 5mg to 7.5mg? Watch This Before You Move Up (Doctor Explains)
2026/11/05
#Zepbound #Tirzepatide #GLP1 #WeightLoss #ObesityMedicine Moving up from Zepbound 5 mg to 7.5 mg? Many people call 7.5 mg "the wall," the dose where nausea, sulfur burps and fatigue hit hard. In this video, I break down what actually changes in your body at 7.5 mg, check 4 popular claims about this dose against the prescribing information and the published trials, and share how to tell whether it's time to move up or stay on 5 mg a little longer. You'll learn:• Why 5 mg is already a full maintenance dose, not a waiting room• What the label really means by "at least 4 weeks"• Why the new dose builds over about 4 weeks instead of hitting all at once• Which side effects are common at 5 mg, and why the stomach slowing fades• The birth control pill rule most people miss• 3 changes to set up before your first 7.5 mg shot• Red flags that mean you should call your doctor 🍳 Free GLP-1 Diet Cookbook (small, lower-fat meals and protein you can get down when your appetite disappears): https://drmohammedpaika.com/newsletter 🎓 GLP-1 Masterclass (realistic expectations, side-effect management, protein and calorie targets, a 12-week home exercise program, and a plan for the long term): https://drmohammedpaika.com I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. This video is for education only and is not medical advice. Dose decisions belong with the clinician who prescribed your medication. TIMESTAMPS0:00 Moving up from 5 mg to 7.5 mg1:13 A patient story: what went wrong at 7.5 mg2:51 Claim 1: GIP "kicks in" at 7.5 mg5:19 Claim 2: 7.5 mg is where real treatment starts6:25 What to eat on injection day (free cookbook)6:50 Claim 3: You should move up every 4 weeks7:59 When to stay on 5 mg vs. move up8:45 Why hunger creeps back late in the week9:03 Claim 4: 7.5 mg hits hardest on injection day9:57 Common side effects at 5 mg10:21 Sulfur burps, reflux and slower stomach emptying11:27 Fatigue, low blood sugar and low blood pressure12:20 On the birth control pill? Read this12:45 3 changes before your first 7.5 mg shot14:36 Constipation: what to try first14:58 If 7.5 mg doesn't agree with you15:25 When to call your doctor15:40 Recap: the 4 claims scored16:36 What you need besides the pen REFERENCES1. ZEPBOUND (tirzepatide) US Prescribing Information. Eli Lilly and Company; revised 8/2026. https://uspl.lilly.com/zepbound/zepbound.html2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/3. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/4. Frias JP, et al. Efficacy and tolerability of tirzepatide in patients with type 2 diabetes: a 12-week study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020;22(6):938-946. https://pubmed.ncbi.nlm.nih.gov/31984598/5. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. https://pubmed.ncbi.nlm.nih.gov/32730231/6. Borner T, et al. GIP receptor agonism attenuates GLP-1 receptor agonist-induced nausea and emesis in preclinical models. Diabetes. 2021;70(11):2545-2553. https://pubmed.ncbi.nlm.nih.gov/34380697/7. Borner T, et al. Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models. Sci Adv. 2025;11(25):eadu1589. https://pubmed.ncbi.nlm.nih.gov/40532005/8. Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Am J Clin Nutr. 2025;122(1):344-367. https://pubmed.ncbi.nlm.nih.gov/40450457/9. Gorgojo-Martínez JJ, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12(1):145. https://pubmed.ncbi.nlm.nih.gov/36614945/ ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
Lower Cholesterol NATURALLY – NO PILLS - Obesity Doctor Explains
2026/11/03
#LDL #Cholesterol #LowerCholesterol #GLP1 #HeartHealth Can you lower LDL cholesterol without a statin? Yes, by roughly 10–15% in real life, and more if you're strict. I'm Dr. Mohammed Paika, board-certified in Internal Medicine and Obesity Medicine. In this video I show you which foods actually lower LDL, how much each one does, and when food alone isn't enough. FREE GLP-1 Diet Cookbook (200 recipes, protein and fiber listed for every serving): https://drmohammedpaika.com/newsletterGLP-1 Masterclass (protein targets + 12-week home exercise program): https://drmohammedpaika.com TIMESTAMPS0:00 Food vs a statin: what one study found1:09 Who this video is for1:26 My LDL story2:12 Why a modest LDL drop matters2:51 The Portfolio diet study (and the catch)4:19 Step 1: Swap saturated fat for unsaturated fat5:23 Coconut oil and eggs6:03 Low-carb diets and LDL6:31 Step 2: Soluble fiber7:59 Step 3: Plant sterols and stanols8:57 Free GLP-1 Diet Cookbook9:25 Step 4: Nuts10:01 Step 5: Soy protein10:39 Step 6: Coffee, weight loss, and exercise11:22 What I see in the hospital13:08 When food isn't enough: LDL 190 or higher13:37 High lipoprotein(a)14:01 High overall risk14:32 Heart disease or diabetes14:50 Red yeast rice and supplements16:37 If statins don't agree with you17:38 GLP-1s and the SELECT trial18:23 When to recheck your lipids18:37 Summary: the plan in 30 seconds19:35 If you're on a GLP-1 REFERENCES1. Jenkins 2003, JAMA: https://pubmed.ncbi.nlm.nih.gov/12876093/2. Jenkins 2011, JAMA: https://pubmed.ncbi.nlm.nih.gov/21862744/3. Chiavaroli 2018, Prog Cardiovasc Dis: https://pubmed.ncbi.nlm.nih.gov/29807048/4. Ference 2017, Eur Heart J: https://pubmed.ncbi.nlm.nih.gov/28444290/5. CTT 2010, Lancet: https://pubmed.ncbi.nlm.nih.gov/21067804/6. Grundy 2018 guideline, Circulation: https://pubmed.ncbi.nlm.nih.gov/30586774/7. Sacks 2017, AHA advisory, Circulation: https://pubmed.ncbi.nlm.nih.gov/28620111/8. Hooper 2020, Cochrane: https://pubmed.ncbi.nlm.nih.gov/32428300/9. Neelakantan 2020, Circulation: https://pubmed.ncbi.nlm.nih.gov/31928080/10. Weggemans 2001, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/11333841/11. Soto-Mota 2024, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/38237807/12. Whitehead 2014, Am J Clin Nutr (industry-funded): https://pubmed.ncbi.nlm.nih.gov/25411276/13. Jovanovski 2018, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/30239559/14. Brown 1999, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/9925120/15. Ras 2014, Br J Nutr (industry authors): https://pubmed.ncbi.nlm.nih.gov/24780090/16. Gylling 2014, EAS consensus, Atherosclerosis: https://pubmed.ncbi.nlm.nih.gov/24468148/17. Del Gobbo 2015, Am J Clin Nutr (part industry-funded): https://pubmed.ncbi.nlm.nih.gov/26561616/18. Blanco Mejia 2019, J Nutr: https://pubmed.ncbi.nlm.nih.gov/31006811/19. Jee 2001, Am J Epidemiol: https://pubmed.ncbi.nlm.nih.gov/11207153/20. Urgert 1997, Annu Rev Nutr: https://pubmed.ncbi.nlm.nih.gov/9240930/21. Dattilo 1992, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/1386186/22. Mann 2014, Sports Med: https://pubmed.ncbi.nlm.nih.gov/24174305/23. Blumenthal 2026 ACC/AHA dyslipidemia guideline, JACC: https://pubmed.ncbi.nlm.nih.gov/41824590/24. Kronenberg 2022, EAS Lp(a) consensus, Eur Heart J: https://pubmed.ncbi.nlm.nih.gov/36036785/25. Gerards 2015, Atherosclerosis: https://pubmed.ncbi.nlm.nih.gov/25897793/26. Gordon 2010, Arch Intern Med: https://pubmed.ncbi.nlm.nih.gov/20975018/27. Sekiguchi 2026, Kidney Int Rep: https://pubmed.ncbi.nlm.nih.gov/41732753/28. Laffin 2023, SPORT, JACC (AstraZeneca-funded): https://pubmed.ncbi.nlm.nih.gov/36351465/29. CTT 2022, Lancet: https://pubmed.ncbi.nlm.nih.gov/36049498/30. Zhang 2013, Ann Intern Med: https://pubmed.ncbi.nlm.nih.gov/23546564/31. Pandor 2009, J Intern Med: https://pubmed.ncbi.nlm.nih.gov/19141093/32. Nissen 2023, CLEAR Outcomes, NEJM (Esperion-funded): https://pubmed.ncbi.nlm.nih.gov/36876740/33. Sabatine 2017, FOURIER, NEJM (Amgen-funded): https://pubmed.ncbi.nlm.nih.gov/28304224/34. Lincoff 2023, SELECT, NEJM (Novo Nordisk-funded): https://pubmed.ncbi.nlm.nih.gov/37952131/ ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
How Do I Stop Gaining Weight After Stopping Mounjaro (Doctor Explains)
2026/10/31
#Ozempic #GLP1 #WeightLoss #Wegovy #Mounjaro Why do most people regain the weight after stopping Ozempic, Wegovy, Mounjaro or Zepbound? As a board-certified Internal Medicine and Obesity Medicine physician, I walk through the 5 reasons weight comes back: your metabolism, your hunger hormones, stopping the medication, your activity level and not watching the scale. For each one, I go through what the research actually shows, including the Biggest Loser follow-up studies, the STEP and SURMOUNT-4 trials and a 2026 BMJ review of 37 studies. Then I share the 5-step plan that gives you the best odds of keeping the weight off, plus my own story of losing 45 pounds, regaining it and losing it again. 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter TIMESTAMPS0:00 The Biggest Loser study1:26 Who this video is for2:08 My own regain story3:45 Reason 1: Your metabolism slows down4:53 Reason 2: Hunger hormones stay turned up6:04 Reason 3: The medication stops8:23 Free GLP-1 Diet Cookbook9:01 Reason 4: Activity doesn't stay high enough11:04 Reason 5: Nobody is watching the scale12:48 The plan: 5 things that give you the best odds15:57 The 30-second scorecard16:45 GLP-1 Masterclass REFERENCES1. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016. https://pubmed.ncbi.nlm.nih.gov/27136388/2. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011. https://pubmed.ncbi.nlm.nih.gov/22029981/3. Wilding JPH, et al. Weight regain after withdrawal of semaglutide: STEP 1 trial extension. Diabetes Obes Metab. 2022. https://pubmed.ncbi.nlm.nih.gov/35441470/4. Rubino D, et al. Continued semaglutide vs placebo for weight loss maintenance (STEP 4). JAMA. 2021. https://pubmed.ncbi.nlm.nih.gov/33755728/5. Aronne LJ, et al. Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024. https://pubmed.ncbi.nlm.nih.gov/38078870/6. West S, et al. Weight regain after cessation of medication for weight management. BMJ. 2026. https://pubmed.ncbi.nlm.nih.gov/41500720/7. Kerns JC, et al. Increased physical activity associated with less weight regain six years after "The Biggest Loser." Obesity. 2017. https://pubmed.ncbi.nlm.nih.gov/29086499/8. Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33951361/9. Wing RR, et al. A self-regulation program for maintenance of weight loss (STOP Regain). N Engl J Med. 2006. https://pubmed.ncbi.nlm.nih.gov/17035649/10. Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr. 2005. https://pubmed.ncbi.nlm.nih.gov/16002825/11. Jensen MD, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation. 2014. https://pubmed.ncbi.nlm.nih.gov/24222017/ This video is for education, not medical advice. Talk to your own doctor before making changes to your medication. 📚 The Weight Equation & The Physician’s PhysiquePhysician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.https://www.drmohammedpaika.com/books 👥 Metabolic Health Communityhttps://www.skool.com/metabolic-health-community-5316👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKABoard-Certified in Internal Medicine and Obesity MedicineCertified Personal Trainer & Nutrition CoachHelping people understand metabolism, hormones, and sustainable health through evidence-based medicine. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
I Prescribe Ozempic: Do "Natural Ozempic" Foods Actually Work?
2026/10/29
#ozempic #glp1 #naturalozempic #berberine #weightloss Do "natural Ozempic" foods actually work? I'm a board-certified internal medicine and obesity medicine physician, and I prescribe GLP-1 medications. In this video, I rank the 7 most popular natural Ozempic claims as real, partly real, or hype: apple cider vinegar, cinnamon, berberine, probiotics, healthy fats, eating order, protein first, and beans. You'll learn what each one can and can't do for your own GLP-1, what the human studies actually show, and which ones I use every day, whether you're on Ozempic, Wegovy, Mounjaro, or Zepbound or not. FREE GLP-1 Diet Cookbook (200 recipes, protein and fiber per serving): https://drmohammedpaika.com/newsletterGLP-1 Masterclass: https://drmohammedpaika.com TIMESTAMPS0:00 Do natural Ozempic foods work?1:10 Why I don't trust shortcuts2:06 Your body already makes GLP-13:19 #1 Apple cider vinegar & cinnamon4:26 #2 Berberine5:52 #3 Probiotics & fermented foods7:09 #4 Healthy fats8:22 #5 Eating order9:22 #6 Protein first10:52 #7 Beans & lentils13:15 The honest answer14:28 The scorecard REFERENCESHolst 2007 Physiol Rev: pubmed.ncbi.nlm.nih.gov/17928588Drucker 2018 Cell Metab: pubmed.ncbi.nlm.nih.gov/29617641Eissele 1992 Eur J Clin Invest: pubmed.ncbi.nlm.nih.gov/1499644Mozaffarian 2025 Am J Clin Nutr (GLP-1 nutrition advisory): pubmed.ncbi.nlm.nih.gov/40450457Ozempic prescribing information: novo-pi.com/ozempic.pdfWilding 2021 NEJM (STEP 1): pubmed.ncbi.nlm.nih.gov/33567185Jastreboff 2022 NEJM (SURMOUNT-1): pubmed.ncbi.nlm.nih.gov/35658024Wilding 2022 (STEP 1 extension): pubmed.ncbi.nlm.nih.gov/35441470Johnston 2004 Diabetes Care (vinegar): pubmed.ncbi.nlm.nih.gov/14694010Kondo 2009 (vinegar, weight): pubmed.ncbi.nlm.nih.gov/19661687Liljeberg 1998 (vinegar, gastric emptying): pubmed.ncbi.nlm.nih.gov/9630389Willershausen 2014 (vinegar, enamel): pubmed.ncbi.nlm.nih.gov/24839821Allen 2013 Ann Fam Med (cinnamon): pubmed.ncbi.nlm.nih.gov/24019277de Moura 2025 Nutr Rev (cinnamon): pubmed.ncbi.nlm.nih.gov/38917435Hlebowicz 2009 (cinnamon, GLP-1): pubmed.ncbi.nlm.nih.gov/19158209Abraham 2010 (coumarin): pubmed.ncbi.nlm.nih.gov/20024932Yin 2008 Metabolism (berberine): pubmed.ncbi.nlm.nih.gov/18442638Xie 2022 (berberine meta-analysis): pubmed.ncbi.nlm.nih.gov/36467075Elahi Vahed 2026 Int J Obes (berberine, weight): pubmed.ncbi.nlm.nih.gov/41310257Guo 2012 (berberine, CYP enzymes): pubmed.ncbi.nlm.nih.gov/21870106Dumitru 2026 (berberine interactions): pubmed.ncbi.nlm.nih.gov/42653808Tolhurst 2012 Diabetes (SCFA, GLP-1): pubmed.ncbi.nlm.nih.gov/22190648Wastyk 2021 Cell (fermented foods): pubmed.ncbi.nlm.nih.gov/34256014Depommier 2019 Nat Med (Akkermansia): pubmed.ncbi.nlm.nih.gov/31263284Thomsen 1999 Am J Clin Nutr (olive oil): pubmed.ncbi.nlm.nih.gov/10357731Carr 2008 (fat, protein, GLP-1): pubmed.ncbi.nlm.nih.gov/18612044Wharton 2022 (GLP-1 GI side effects): pubmed.ncbi.nlm.nih.gov/34775881Shukla 2015 Diabetes Care (food order): pubmed.ncbi.nlm.nih.gov/26106234Shukla 2017 (carbs last, GLP-1): pubmed.ncbi.nlm.nih.gov/28989726Jakubowicz 2014 Diabetologia (whey): pubmed.ncbi.nlm.nih.gov/25005331Smedegaard 2023 (whey meta-analysis): pubmed.ncbi.nlm.nih.gov/37536867Neeland 2024 (lean mass on GLP-1s): pubmed.ncbi.nlm.nih.gov/38937282KDIGO 2024 (CKD guideline): pubmed.ncbi.nlm.nih.gov/38490803Chambers 2015 Gut (propionate): pubmed.ncbi.nlm.nih.gov/25500202Nilsson 2013 PLoS One (beans): pubmed.ncbi.nlm.nih.gov/23577078Li 2014 Obesity (pulses, satiety): pubmed.ncbi.nlm.nih.gov/24820437Kim 2016 Am J Clin Nutr (pulses, weight): pubmed.ncbi.nlm.nih.gov/27030531Winham 2011 Nutr J (beans, gas): pubmed.ncbi.nlm.nih.gov/22104320Duyff 2011 (rinsing canned beans): doi.org/10.1080/15428052.2011.582405USDA FoodData Central: fdc.nal.usda.govIOM Dietary Reference Intakes 2005: doi.org/10.17226/10490 ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
6 Nutrients GLP 1s May Be Depleting — A Doctor Explains Why
2026/10/27
#GLP1 #Ozempic #Zepbound #VitaminDeficiency #WeightLoss Taking Ozempic, Wegovy, Mounjaro, or Zepbound exactly as prescribed and still feeling more tired than you expected, noticing your hair shedding, or wondering if a multivitamin is enough? In one trial, people on semaglutide ate about 35% less at an all-you-can-eat lunch. That's why these drugs work, but less food also means less protein, fiber, vitamins, and minerals unless you choose what's left on purpose. In this video, I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. I break down 6 nutrients you can run low on with GLP-1 medications, how strong the evidence really is for each one, and what to do about it. You'll also get a simple lab checklist to discuss with your doctor, plus the rare deficiency (#6) that can put you in the hospital. 🍳 FREE GLP-1 Diet Cookbook (200 recipes, protein and fiber listed for every serving): https://drmohammedpaika.com/newsletter🎓 GLP-1 Masterclass (protein targets, side effects, 12-week home exercise program, what happens when you stop, plus new modules on nausea, constipation, diarrhea, heartburn, and fatigue): https://drmohammedpaika.com📩 Questions: [email protected] ⏱️ TIMESTAMPS0:00 Eating less on a GLP-1? Here's the problem1:25 Why nutrients run low on these drugs2:15 #1 Protein: protecting your muscle3:23 #2 Fiber and constipation4:12 #3 Vitamin D5:36 Free GLP-1 Diet Cookbook6:05 #4 Calcium and your bones7:17 #5 Vitamin B12 (if you take metformin)8:18 Iron, magnesium, and zinc: reality check9:18 Hair loss: real, and usually temporary10:15 #6 Thiamine (B1) and Wernicke encephalopathy11:43 Red flags: when to call your doctor or go to the ER12:29 Your lab checklist13:50 Pregnancy and birth control on GLP-1s14:26 GLP-1 Masterclass 📚 REFERENCES1. Friedrichsen M, et al. Diabetes Obes Metab. 2021;23:754-62. https://pubmed.ncbi.nlm.nih.gov/33269530/2. Butsch WS, et al. Obes Pillars. 2025;15:100186. https://pubmed.ncbi.nlm.nih.gov/40584822/3. Look M, et al. (SURMOUNT-1 body composition) Diabetes Obes Metab. 2025;27:2720-9. https://pubmed.ncbi.nlm.nih.gov/39996356/4. Wilding JPH, et al. (STEP 1) N Engl J Med. 2021;384:989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/5. Mozaffarian D, et al. (ACLM/ASN/OMA/TOS advisory) Am J Clin Nutr. 2025;122:344-67. https://pubmed.ncbi.nlm.nih.gov/40450457/6. Johnson B, et al. Front Nutr. 2025;12:1566498. https://pubmed.ncbi.nlm.nih.gov/40352260/7. Wortsman J, et al. Am J Clin Nutr. 2000;72:690-3. https://pubmed.ncbi.nlm.nih.gov/10966885/8. Lai CH, et al. Arch Osteoporos. 2026;21. https://pubmed.ncbi.nlm.nih.gov/42920024/9. Beaudart C, et al. Drugs. 2026;86:1661-91. https://pubmed.ncbi.nlm.nih.gov/42730869/10. Aroda VR, et al. (Diabetes Prevention Program) J Clin Endocrinol Metab. 2016;101:1754-61. https://pubmed.ncbi.nlm.nih.gov/26900641/11. ADA Standards of Care in Diabetes—2026, Section 3. Diabetes Care. 2026;49(Suppl 1):S50-S60. https://pubmed.ncbi.nlm.nih.gov/41358891/12. Alhamdan Y, et al. Diabetes Obes Metab. 2026;28:5163-73. https://pubmed.ncbi.nlm.nih.gov/41913529/13. Shao SC, et al. PLoS Med. 2026;23:e1004968. https://pubmed.ncbi.nlm.nih.gov/41790761/14. Kanai R, et al. Obes Pillars. 2024;9:100098. https://pubmed.ncbi.nlm.nih.gov/38230266/15. Gras C, et al. Eur J Clin Nutr. 2025;79:1160-3. https://pubmed.ncbi.nlm.nih.gov/40908328/16. Bidesie J, et al. Obesity (Silver Spring). 2026;34(Suppl 2):64-9. https://pubmed.ncbi.nlm.nih.gov/42399213/17. Wegovy prescribing information (rev. 06/2026): https://www.novo-pi.com/wegovy.pdf18. Zepbound prescribing information: https://uspl.lilly.com/zepbound/zepbound.html19. Ozempic prescribing information: https://www.novo-pi.com/ozempic.pdf20. Mounjaro prescribing information: https://uspl.lilly.com/mounjaro/mounjaro.html21. NIH Office of Dietary Supplements fact sheets (vitamin D, calcium, magnesium, thiamin): https://ods.od.nih.gov/factsheets/list-all/22. American Academy of Dermatology, hair shedding: https://aad.org/hair-shedding23. Institute of Medicine, Dietary Reference Intakes (fiber), 2005: https://nap.nationalacademies.org/catalog/10490 ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
Not Losing Weight on GLP 1 With PCOS? A Doctor Explains Why
2026/10/24
#PCOS #GLP1 #PMOS #Semaglutide #Tirzepatide Not losing weight on GLP-1 with PCOS? You're not imagining it, and it's not a willpower problem. In this video, I explain why semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) can stall in women with PCOS, now officially renamed PMOS (polyendocrine metabolic ovarian syndrome), and the 4 things doctors do to get weight loss moving again. You'll learn the 3 hormonal roadblocks behind a PCOS stall (high insulin, androgens and belly fat, and your own GLP-1 system), why standard dosing often isn't enough, how tirzepatide compares with semaglutide, when metformin or inositol makes sense, which labs to track (fasting insulin, HOMA-IR, free testosterone, SHBG, TSH, A1c and lipids), and how to tell your treatment is working even when the scale isn't. 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter Timestamps 00:00 Why GLP-1 weight loss stalls with PCOS00:55 About me01:21 PCOS is now PMOS: why the name changed02:36 Insulin resistance in PCOS: the numbers03:12 Roadblock #1: Hyperinsulinemia04:44 Roadblock #2: Androgens and belly fat06:10 Muscle: a shortcut around insulin resistance06:57 Roadblock #3: Your own GLP-1 system07:55 Why standard GLP-1 dosing stalls09:11 Metabolic adaptation and normal plateaus09:51 Fix #1: Right drug, right dose10:36 Tirzepatide vs semaglutide (and PCOS data)11:39 Retatrutide11:56 Pregnancy and birth control on GLP-1s12:22 Fix #2: Metformin, combination therapy and inositol13:57 Fix #3: Labs to track, not just the scale15:33 Fix #4: Body composition and protecting muscle16:39 Non-scale wins to watch17:09 GLP-1 Masterclass17:30 Summary and what happens if you stop References 1. Teede HJ, et al. 2023 International Evidence-based Guideline for PCOS. J Clin Endocrinol Metab. 2023;108(10):2447-2469.2. PCOS renamed PMOS. The Lancet, May 12, 2026; Monash/MCHRI terminology summary, 2026.3. Stepto NK, et al. Hum Reprod. 2013;28(3):777-784.4. Cassar S, et al. Hum Reprod. 2016;31(11):2619-2631.5. Nestler JE. Semin Reprod Endocrinol. 1997;15(2):111-122.6. O'Reilly MW, et al. J Clin Endocrinol Metab. 2017;102(9):3327-3339.7. Zhu S, et al. Front Endocrinol. 2021;12:697223.8. Karolinska Institutet doctoral thesis on adipocyte lipolysis in PCOS.9. Moro C, et al. J Clin Endocrinol Metab. 2009;94(7):2579-2586.10. Aydin K, et al. Clin Endocrinol. 2014;81(4):588-592.11. Güneşli I, et al. Endocrine Abstracts. 2025;110:RC5.2.12. An impaired GLP-1 response is associated with prediabetes in PCOS with obesity. PMC6833370.13. Glintborg D, et al. Endocr Connect. 2017;6(4):267-277.14. Wegovy (semaglutide) US Prescribing Information, including Wegovy HD 7.2 mg (FDA, 2026).15. Zepbound (tirzepatide) US Prescribing Information.16. Carmina E, Longo RA. J Clin Med. 2023;12(18):5921.17. Alawami F, et al. Ir J Med Sci. 2026;195(1):131-136.18. Fothergill E, et al. Obesity. 2016;24(8):1612-1619.19. Thomas MK, et al. J Clin Endocrinol Metab. 2021;106(2):388-396.20. Tirzepatide vs semaglutide on beta-cell function and insulin sensitivity. J Clin Endocrinol Metab. 2024;109(12):3046-3054.21. Aronne LJ, et al. SURMOUNT-5. N Engl J Med. 2025;393(1):26-36.22. Clift AK, et al. J Endocr Soc. 2026;10(9):bvag177.23. PERIODS trial (tirzepatide in PCOS). ClinicalTrials.gov NCT07326111.24. Jastreboff AM, et al. TRIUMPH-1 (retatrutide). N Engl J Med. 2026.25. Jensterle M, et al. Exp Ther Med. 2016;11(4):1194-1200.26. Zhang W, et al. Metab Target Organ Damage. 2026;6:10.27. Fitz V, et al. J Clin Endocrinol Metab. 2024;109(6):1630-1655.28. Matthews DR, et al. Diabetologia. 1985;28(7):412-419.29. Ding X, et al. Front Endocrinol. 2018;9:700.30. Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002; Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216.31. Jensterle M, et al. Front Endocrinol. 2024;15:1366940. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
TRT for Men Over 50: Why a GLP-1 Might Fix Your Testosterone First (Doctor Explains)
2026/10/22
#Testosterone #TRT #LowTestosterone #GLP1 #weightloss  Is “male menopause” real, and do you actually need testosterone therapy? As an internal medicine and obesity medicine physician, I break down what the research really shows about low testosterone after 50, including: How common true late-onset hypogonadism actually is (hint: far less than the ads suggest)Why excess weight is the #1 fixable cause of low testosterone, and how GLP-1s like Ozempic and Mounjaro may help your own testosterone come backHow to get tested properly (morning, fasting, repeated)What TRT can and can’t do, according to the Testosterone TrialsWhat the TRAVERSE trial showed about heart safety, plus the side effects that did go upThe newest FDA label changes and the HHS proposalA simple 5-question checklist to work through with your doctor before you ever start TRT 📘 FREE GLP-1 Diet Cookbook (high-protein meals for a smaller appetite): https://drmohammedpaika.com/newsletter 🎓 GLP-1 Masterclass (calorie and protein targets, side effects, and a 12-week home strength program): https://drmohammedpaika.com This video is for educational purposes only and is not medical advice. Talk to your own doctor before starting, stopping, or changing any medication. TIMESTAMPS0:00 Is low testosterone really the answer?1:34 Is “male menopause” even real?3:13 The biggest driver of low testosterone: weight4:04 How GLP-1s may raise your own testosterone5:00 The other side: semaglutide and low T6:03 How to know if you actually have low testosterone7:28 What TRT really does: the Testosterone Trials8:54 Is testosterone safe for your heart? (TRAVERSE)10:29 FDA label changes and the HHS proposal11:04 On a GLP-1 and testosterone at the same time?12:06 Should everyone consider hormone therapy?13:08 5 questions to ask before starting TRT14:24 What to watch next 📚 REFERENCES Gray A, et al. Massachusetts Male Aging Study. J Clin Epidemiol. 1991;44:671-684.Feldman HA, et al. Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589-598.Wu FCW, et al. European Male Ageing Study: late-onset hypogonadism. N Engl J Med. 2010;363:123-135.Corona G, et al. Weight loss and obesity-associated hypogonadism (meta-analysis). Eur J Endocrinol. 2013;168:829-843.Portillo-Canales S, Dhindsa S, et al. Incretin-based drugs and testosterone in men. ENDO 2025 abstract RF27-03; Endocr Pract. 2026;32:696-703.Liao B, Able C, et al. Semaglutide and hypogonadism/ED in non-diabetic men. SMSNA 2023 abstract 157; Able C, et al. Int J Impot Res. 2024.Bhasin S, et al. Testosterone therapy in men with hypogonadism: Endocrine Society guideline. J Clin Endocrinol Metab. 2018;103:1715-1744.Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423-432.Snyder PJ, et al. Effects of testosterone treatment in older men (Testosterone Trials). N Engl J Med. 2016;374:611-624.Qaseem A, et al. Testosterone treatment in men with age-related low testosterone: ACP guideline. Ann Intern Med. 2020;172:126-133.Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). N Engl J Med. 2023;389:107-117.Snyder PJ, et al. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390:203-211.U.S. FDA. Class-wide labeling changes for testosterone products. Feb 28, 2025.U.S. HHS. Request to update testosterone replacement therapy labeling. June 18, 2026 (proposed).U.S. FDA. Removal of boxed warnings on menopausal hormone therapy. Nov 2025.Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002.Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
Microdosing Zepbound & Ozempic: How Low Can You Go and Still Keep the Weight Off? (Doctor Explains)
2026/10/20
#GLP1 #Microdosing #Zepbound #Ozempic #WeightLossMaintenance Microdosing Zepbound & Ozempic: How Low Can You Go and Still Keep the Weight Off? You hit your goal weight. Now the question is: do you have to stay on this dose forever? More and more people are cutting their GLP-1 dose to a fraction or stretching their shots to every 10 to 14 days, hoping to save money, cut side effects, and keep the weight off. I'm Dr. Mohammed Paika, a board-certified internal medicine and obesity medicine physician and practicing hospitalist. In this video I break down what the research actually shows about lower-dose GLP-1 maintenance, and what it doesn't show yet. 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter TIMESTAMPS0:00 Do I have to stay on this dose forever?1:24 The rebound: what happens when you stop2:49 Why microdosing is trending now4:01 What is microdosing? The minimal effective dose5:02 Two approaches: dose reduction vs. interval spacing6:01 What happens at lower doses7:35 Muscle preservation9:14 What the evidence says: SURMOUNT-MAINTAIN12:03 Why the weight comes back: the set point13:35 Why people want a lower dose: cost, supply, side effects14:16 The 4 risks of going too low17:06 My step-down framework18:38 How low can you go? The bottom line REFERENCES1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.3. SURMOUNT-4 post hoc analysis of weight regain. JAMA Intern Med. 2025.4. Evidation. Real-world GLP-1 dosing behaviors (preliminary survey). December 2025.5. Bickel CS, Cross JM, Bamman MM. Exercise dosing to retain resistance training adaptations in young and older adults. Med Sci Sports Exerc. 2011;43(7):1177-1187.6. Wegovy (semaglutide), Ozempic (semaglutide) and Zepbound (tirzepatide) US prescribing information.7. Hackensack Meridian Health. Is microdosing GLP-1s safe? May 2026.8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.9. Nauck MA, et al. Rapid tachyphylaxis of the GLP-1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.10. O'Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649.11. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.12. Wilding JPH, et al. STEP 1 body composition (DXA) substudy. J Endocr Soc. 2021;5(Suppl 1):A16-A17.13. Look M, et al. SURMOUNT-1 body composition (DXA) substudy. Diabetes Obes Metab. 2025.14. SURMOUNT-MAINTAIN. Tirzepatide maximum dose vs. 5 mg vs. placebo for weight maintenance. Lancet. May 2026.15. Gudbergsen H, et al. Semaglutide with a digital weight-management program in Denmark (Embla), lowest effective dose. 2025.16. Embla semaglutide tapering study. European Congress on Obesity. 2024.17. ClinicalTrials.gov NCT07783854. Randomized dose-tapering regimen of semaglutide for weight-loss maintenance.18. Eli Lilly. ATTAIN-MAINTAIN topline results (orforglipron). December 2025.19. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604.20. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612-1619.21. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. 2025.22. Eli Lilly. Zepbound KwikPen instructions for use and FAQ (priming). 2026.23. US FDA. Dosing errors with compounded semaglutide. July 26, 2024. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
Splitting Your Ozempic or Mounjaro Dose: Is It Safe? (Doctor Explains)
2026/10/17
#Ozempic #Mounjaro #GLP1 #Tirzepatide #WeightLossDoctor Should you split your weekly Ozempic, Wegovy, Mounjaro, or Zepbound shot into two smaller doses? Lots of you have asked me about this in the comments. People split their dose to ease the nausea in the first few days and keep food noise down late in the week. In this video, I explain what the pharmacokinetics predict, what the clinical trials did and didn’t test, and the hidden risks most people never hear about. As an obesity medicine physician, I walk you through half-life, steady state, peak and trough levels, and a simple model of what splitting does to your drug levels. Then I cover the safer, approved ways your doctor can smooth out your week instead. 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com ⚠️ This video is for education only and is not personal medical advice. Don’t change your dose, your schedule or your device without talking to the clinician who prescribes it. TIMESTAMPS0:00 Should you split your weekly GLP-1 dose?1:17 Why people split their dose: the peak and the trough2:56 Half-life and steady state3:27 What splitting does to your drug levels5:11 Side effects: the peak or the dose increase?6:09 What the clinical trials actually tested7:52 Plausible vs. proven8:21 Hidden risks: pens and vials9:16 Compounded vials and dosing errors10:44 Strategy 1: Slow the titration11:23 Strategy 2: Find your lowest effective dose11:56 Strategy 3: Eat around injection day12:35 Strategy 4: Timing and short-term support12:58 Strategy 5: Change the molecule13:45 The verdict14:14 3 questions for your doctor REFERENCES Wegovy (semaglutide) US Prescribing Information, Novo Nordisk. https://www.novo-pi.com/wegovy.pdfZepbound (tirzepatide) US Prescribing Information, Eli Lilly. https://medlibrary.org/lib/rx/meds/zepbound/page/5/Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg. Diabetes Obes Metab. 2022;24:94-105.Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.Aronne LJ, et al. Tirzepatide vs. semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.O’Neil PM, et al. Semaglutide vs. liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649.Frias JP, et al. Tirzepatide dose-escalation regimens. Diabetes Obes Metab. 2020;22:938-946.Huang KP, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature. 2024;632:585-593.Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58:7370-7380.Cengiz A, et al. Alternative dosing regimens of GLP-1 receptor agonists. Diabetes Obes Metab. 2025;27:2251-2258.Ji L, et al. GZR18 once-weekly or bi-weekly dosing: phase 1b/2a trial. Cell Rep Med. 2026;7:102743.FDA. Dosing errors associated with compounded injectable semaglutide (July 2024). https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compoundedISMP. Errors possible when microdosing (counting clicks) to dose weight loss medicines (2025). https://www.consumermedsafety.org/safety-articles/errors-possible-when-microdosing-counting-clicks-to-dose-weight-loss-medicinesLilly Medical: Zepbound single-dose vial and KwikPen guidance. https://medical.lilly.comAmerica’s Poison Centers semaglutide call data, as reported by CNN/ABC7 (Dec 2023). https://abc7ny.com/fda-poison-control-centers-weight-loss-drug-diabetes/14178159/Foundayo (orforglipron) US Prescribing Information, Eli Lilly.Ryan H, et al. OxyContin’s 12-hour problem. Los Angeles Times. 2016. Modeled peak and trough figures come from a simple one-compartment model built on label half-lives. They are illustrative estimates, not blood levels measured in a trial. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
How to REMOVE Food Noise (It’s Not Willpower) | Doctor Explains
2026/10/15
#FoodNoise #GLP1 #Ozempic #WeightLoss #ObesityMedicine Can't stop thinking about food, even right after a full meal? That constant chatter has a name: food noise. I explain what it is, why GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound quiet it, and why it often returns when people stop them. You'll learn the 2 drivers behind it, a simple test to tell real hunger from food noise, and 9 evidence-based strategies to turn it down, with or without medication. Every claim is referenced below. 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com TIMESTAMPS0:00 Can't stop thinking about food?1:32 Food noise vs. real hunger2:02 Why GLP-1s made food noise famous2:41 What happens when you stop semaglutide3:02 Your brain's 2 appetite systems4:13 Driver 1: Physical4:24 Pattern 1: Eating too little, too early7:20 Driver 2: Psychological7:30 Trigger 1: Habit (the Netflix effect)9:02 How sleep and stress turn up the volume9:29 The plain-food test: hunger or noise?9:57 9 strategies to quiet food noise10:07 1. Protein-forward breakfast10:31 2. Eat your carbs last10:58 3. Protect your sleep11:16 4. Edit your food cues11:39 5. Plan and prep once a week13:27 Your 7-day experiment13:42 When food noise is still loud: GLP-1 medications14:15 4 important caveats15:11 When it's more than noise REFERENCES1. Hayashi 2023, Nutrients: https://pubmed.ncbi.nlm.nih.gov/38004203/2. Blundell 2017, Diabetes Obes Metab: https://pmc.ncbi.nlm.nih.gov/articles/PMC5573908/3. van Bloemendaal 2014, Diabetes 63(12):41864. Wilding 2022, Diabetes Obes Metab: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/5. Lutter 2009, J Nutr: https://pubmed.ncbi.nlm.nih.gov/19176746/6. Berridge 2009, Physiol Behav: https://pmc.ncbi.nlm.nih.gov/articles/PMC2717031/7. Boswell 2016, Obes Rev: https://canlab.yale.edu/sites/default/files/boswel-kober_2016_obesityreviews.pdf8. Wood & Neal 2007, Psychol Rev 114(4):8439. Keys 1950, The Biology of Human Starvation (Minnesota Starvation Experiment)10. Sumithran 2011, NEJM: https://pubmed.ncbi.nlm.nih.gov/22029981/11. Rolls 2017, Nutr Bull: https://pubmed.ncbi.nlm.nih.gov/29151813/12. Dennis 2010, Obesity: https://pubmed.ncbi.nlm.nih.gov/19661958/13. World Health Organization 2023, Guideline on non-sugar sweeteners (May 15, 2023)14. Ludwig 1999, Pediatrics: https://pubmed.ncbi.nlm.nih.gov/10049982/15. Lennerz 2013, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/23803881/16. Weigle 2005, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/16002798/17. Hall 2019, Cell Metab: https://pubmed.ncbi.nlm.nih.gov/31105044/18. Leidy 2015, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/25926512/19. Neal et al. 2011, Pers Soc Psychol Bull 37(11):142820. Tomova 2020, Nat Neurosci: https://dspace.mit.edu/handle/1721.1/13831321. Spiegel 2004, Ann Intern Med: https://pubmed.ncbi.nlm.nih.gov/15583226/22. Hoertel 2014, Nutr J: https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-13-8023. Leidy 2013, Am J Clin Nutr: https://pmc.ncbi.nlm.nih.gov/articles/PMC3718776/24. Tasali 2022, JAMA Intern Med: https://pubmed.ncbi.nlm.nih.gov/35129580/25. Hunter 2018, Appetite: https://pubmed.ncbi.nlm.nih.gov/29183701/26. Ducrot 2017, Int J Behav Nutr Phys Act: https://pubmed.ncbi.nlm.nih.gov/28153017/27. Lieberman 2007, Psychol Sci: https://pubmed.ncbi.nlm.nih.gov/17576282/28. Zaccaro 2018, Front Hum Neurosci: https://pubmed.ncbi.nlm.nih.gov/30245619/29. Gollwitzer & Sheeran 2006, Adv Exp Soc Psychol 38:6930. Taylor & Oliver 2009, Appetite 52(1):15531. Ledochowski 2015, PLoS One: https://pmc.ncbi.nlm.nih.gov/articles/PMC4356559/32. Buffey 2022, Sports Med: https://pubmed.ncbi.nlm.nih.gov/35147898/33. Wilding 2021, NEJM (STEP 1): https://www.nejm.org/doi/full/10.1056/NEJMoa203218334. Hudson 2007, Biol Psychiatry: https://pubmed.ncbi.nlm.nih.gov/16815322/35. Tataranni 1996, Am J Physiol: https://pubmed.ncbi.nlm.nih.gov/8770026/36. Shukla 2015, Diabetes Care: https://pmc.ncbi.nlm.nih.gov/articles/PMC4876745/ ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

Podcast reviews

Read Dr. Paika Podcast podcast reviews


5 out of 5
2 reviews

Podcast sponsorship advertising

Start advertising on Dr. Paika Podcast relevant audience podcasts


What do you want to promote?